Amikacin Eases MAC Lung Disease in First-Line Treatment

(MedPage Today) -- Amikacin liposome inhalation suspension (ALIS) improved symptoms and infection clearance in treatment-naive Mycobacterium avium complex (MAC) lung disease, the ENCORE trial showed. For the primary endpoint, the aminoglycoside...
Source
MedPage Today
Opens original article in a new tab



